



## Correction to: Ambrisentan ± tadalafil in WHO functional class II/III pulmonary arterial hypertension: a guide to its use in the EU

Katherine A. Lyseng-Williamson<sup>1</sup> · Jürgen Behr<sup>2</sup>

Published online: 23 November 2018  
© Springer Nature Switzerland AG 2018

**Correction to: Drugs & Therapy Perspectives**  
<https://doi.org/10.1007/s40267-018-0531-1>

Page 294, column 1, first sentence: the following text, which previously read:

“In a secondary analysis of survival outcomes in the modified intent-to-treat population of AMBITION, mortality rates did not differ to a significant extent between the ambrisentan + tadalafil and pooled monotherapy groups at the end of the 24-week trial (10 vs 14% of patients; HR 0.67; 95% CI 0.42–1.08; log-rank  $p = 0.10$ ) [24]”.

Should read:

“In a secondary analysis of survival outcomes in the modified intent-to-treat population of AMBITION, mortality rates did not differ to a significant extent between the ambrisentan + tadalafil and pooled monotherapy groups at the end of the study (10 vs 14% of patients; HR 0.67; 95% CI 0.42–1.08; log-rank  $p = 0.10$ ; median time on study drug 96 and 91 weeks, respectively) [24]”.

---

The original article can be found online at <https://doi.org/10.1007/s40267-018-0531-1>.

---

✉ Katherine A. Lyseng-Williamson  
dtp@adis.com

<sup>1</sup> Springer, Mairangi Bay, Private Bag 65901, Auckland 0754, New Zealand

<sup>2</sup> Department of Internal Medicine V, Comprehensive Pneumology Centre, University of Munich, Munich, Germany